447 related articles for article (PubMed ID: 21158686)
21. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
22. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
Bai YL; Liu HB; Sun B; Zhang Y; Li Q; Hu CW; Zhu JX; Gong DM; Teng X; Zhang Q; Yang BF; Dong DL
J Mol Cell Cardiol; 2011 Nov; 51(5):876-80. PubMed ID: 21820442
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.
Sorota S; Zhang XS; Margulis M; Tucker K; Priestley T
Assay Drug Dev Technol; 2005 Feb; 3(1):47-57. PubMed ID: 15798395
[TBL] [Abstract][Full Text] [Related]
24. Ion channel pharmacology under flow: automation via well-plate microfluidics.
Spencer CI; Li N; Chen Q; Johnson J; Nevill T; Kammonen J; Ionescu-Zanetti C
Assay Drug Dev Technol; 2012 Aug; 10(4):313-24. PubMed ID: 22574656
[TBL] [Abstract][Full Text] [Related]
25. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
Tao H; Santa Ana D; Guia A; Huang M; Ligutti J; Walker G; Sithiphong K; Chan F; Guoliang T; Zozulya Z; Saya S; Phimmachack R; Sie C; Yuan J; Wu L; Xu J; Ghetti A
Assay Drug Dev Technol; 2004 Oct; 2(5):497-506. PubMed ID: 15671647
[TBL] [Abstract][Full Text] [Related]
26. Assessment of temperature-induced hERG channel blockade variation by drugs.
Kauthale RR; Dadarkar SS; Husain R; Karande VV; Gatne MM
J Appl Toxicol; 2015 Jul; 35(7):799-805. PubMed ID: 25348819
[TBL] [Abstract][Full Text] [Related]
27. H(1) antihistamine drug promethazine directly blocks hERG K(+) channel.
Jo SH; Hong HK; Chong SH; Lee HS; Choe H
Pharmacol Res; 2009 Nov; 60(5):429-37. PubMed ID: 19497368
[TBL] [Abstract][Full Text] [Related]
28. Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Fujii M; Ohya S; Yamamura H; Imaizumi Y
J Biomol Screen; 2012 Jul; 17(6):773-84. PubMed ID: 22498908
[TBL] [Abstract][Full Text] [Related]
29. QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles.
Kii Y; Hayashi S; Tabo M; Shimosato T; Fukuda H; Itoh T; Amano H; Saito M; Morimoto H; Yamada K; Kanda A; Ishitsuka T; Yamazaki T; Kiuchi Y; Taniguchi S; Mori T; Shimizu S; Tsurubuchi Y; Yasuda S; Kitani S; Shimada C; Kobayashi K; Komeno M; Kasai C; Hombo T; Yamamoto K
J Pharmacol Sci; 2005; 99(5):449-57. PubMed ID: 16493186
[TBL] [Abstract][Full Text] [Related]
30. Propofol inhibits hERG K
Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
[TBL] [Abstract][Full Text] [Related]
31. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
32. SKF-96365 blocks human ether-à-go-go-related gene potassium channels stably expressed in HEK 293 cells.
Liu H; Yang L; Chen KH; Sun HY; Jin MW; Xiao GS; Wang Y; Li GR
Pharmacol Res; 2016 Feb; 104():61-9. PubMed ID: 26689773
[TBL] [Abstract][Full Text] [Related]
33. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
Zhao J; Wang Q; Xu J; Zhao J; Liu G; Peng S
Eur J Pharmacol; 2011 Jun; 660(2-3):259-67. PubMed ID: 21497594
[TBL] [Abstract][Full Text] [Related]
34. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
35. Solubility assessment and on-line exposure confirmation in a patch-clamp assay for hERG (human ether-a-go-go-related gene) potassium channel inhibition.
Rast G; Guth BD
J Pharmacol Toxicol Methods; 2014; 70(2):182-7. PubMed ID: 25117629
[TBL] [Abstract][Full Text] [Related]
36. Indexing molecules for their hERG liability.
Rayan A; Falah M; Raiyn J; Da'adoosh B; Kadan S; Zaid H; Goldblum A
Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540
[TBL] [Abstract][Full Text] [Related]
37. Introduction of a modular automated voltage-clamp platform and its correlation with manual human Ether-à-go-go related gene voltage-clamp data.
Scheel O; Himmel H; Rascher-Eggstein G; Knott T
Assay Drug Dev Technol; 2011 Dec; 9(6):600-7. PubMed ID: 21675869
[TBL] [Abstract][Full Text] [Related]
38. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
Zhang P; Xing J; Luo A; Feng J; Liu Z; Gao C; Ma J
J Pharm Pharmacol; 2013 Sep; 65(9):1321-8. PubMed ID: 23927470
[TBL] [Abstract][Full Text] [Related]
39. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
Zeng H; Lozinskaya IM; Lin Z; Willette RN; Brooks DP; Xu X
J Pharmacol Exp Ther; 2006 Nov; 319(2):957-62. PubMed ID: 16928897
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of hERG potassium channel blockade by antipsychotics.
Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2007 Sep; 29(7):457-65. PubMed ID: 17982510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
